+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

3D Bioprinting Market - Global Outlook and Forecast 2022-2027

  • PDF Icon


  • 320 Pages
  • October 2022
  • Region: Global
  • Arizton
  • ID: 5671326
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The global 3D Bioprinting market is expected to grow at a CAGR of 18.45% during 2022-2027.


  • The 3D Bioprinting is a technique that allows the production of biocompatible materials and complex 3D functional living tissues. It has enabled numerous researchers and manufacturers to mimic the natural tissue microenvironment into an in-house printed 3D tissue model. It has an immense impact in the field of medicine and healthcare.
  • The 3D bioprinting market focuses on developing application-specific bio-inks and new biomaterials, which are crucial in advancing Bio-printing tissues and organs for clinical use. Bioprinters and bio-printed tissues have gained significant interest in medicine and pharmaceutics. Besides, bioprinting technology has a broad utility in various application areas such as tissue engineering and regenerative medicine (RM), transplantation, cancer research and drug screening, and high-throughput assays. Bioprinting technology has the most recognized application in tissue engineering. Bioprinters are used to manufacture scaffolds and fabricate anatomically correct patient-specific constructs. In vitro bio-printed tissues such as skin, nerve and bone have been implanted on animals to evaluate their functionality, neovascularization, and engraftment with the host. Bioprinting's future application is expected to be mostly in organ transplantation and drug & toxicity screening.
  • 4D bioprinting can overcome many limitations of 3D printing; hence, it has become a new field in RM and tissue engineering markets. When compared to 3D printing, 4D printing offers various advantages such as fast growth of smart and multi-materials, more flexible and deformable structures, and can add more potential applications to both 4D and 3D printing. The emergence of 4D bio-printing is gaining momentum in disease management and healthcare innovation.


  • Bio-inks with lower biocompatibility and mechanical strength
  • Lower resolution and speed of bioprinter
  • Vasculature of tissue structures/constructs is an important challenge in Bio-printing as the tissues need continuous nutrients and oxygen.
  • Ethical and legal issues with 3D Bioprinting
  • The high cost of the method makes it unaffordable to developing countries.
  • Because Bio-printing is a new and novel technology, it should be studied appropriately to ensure it will be safe for humans.
  • Numerous Bioprinting companies have emerged in the market. Bioprinting can become a new gold standard for the bio-fabrication of tissues in the field of regenerative medicine.
  • About 80% of the market comprises established companies, while 20% are start-ups with strong economic growth. Among all types of bioprinters, extrusion-based bioprinters are used most widely because of their lower cost and ease to use. In comparison, the second most common Bio-printing technology is Inkjet-based. Currently, inkjet technology is included in most extrusion-based bioprinters, commercially available as an additional printing head.
  • Stereolithography-based bioprinters are a new addition to the bio-printing industry. Laser-assisted bioprinters are one of the most expensive bioprinters. Laser-assisted bioprinters can reach the highest resolutions on the market. The global bioprinting market is growing at a faster rate not only in terms of quantity but also in terms of diversification of the technologies developed and offered. The bioprinting companies are relatively dispersed across all continents. Globally, the US remains the most significant player, exceeding all the other countries. Several Bio-printing companies across the globe currently manufacture commercially available 3D bioprinters, which indicates that the field of Bio-printing is growing rapidly, and many start-ups are entering the market. The technological innovations associated with bioprinters and bio-inks are also increasing rapidly.


  • One of the biggest trends in technological innovations is the development of magnetic bioprinters, Organ. But, a magnetic bioprinter was developed by a Russian company, 3D Bioprinting Solutions. Furthermore, the Japanese company Cyfuse Biomedical developed a platform that allows the creation of scaffold-free tissues using the Kenzan Bio-printing method to manipulate spheroids. Conversely, some companies, such as Germany-based Cellbricks, prefer to produce complex 3D printed cell culture structures with a proprietary non-commercial stereolithography-based Bio-printing platform.
  • The enhancement in printing resolution, speed, and cost reduction are common challenges to be faced in the coming future. Germany-based Cellbricks prefer to produce complex 3D-printed cell culture structures with a proprietary non-commercial stereolithography-based Bio-printing platform. Furthermore, some enterprises try to propose bioprinters with more degrees of freedom to increase system flexibility and the range of printable features, like the American company Advanced Solutions, which has patented a six-axis robotic extrusion-based bioprinter arm, BioAssembleBot 400, which can load up to ten independent biomaterials during a single print run.
  • Poietis, a France based Bio-printing company, focuses on laser-assisted Bio-printing combined with extrusion-based and inkjet-based technologies supported via a proprietary privacy impact assessment (PIA) software to reconstitute the 3D picture of a complete tissue with all layers. Aspect Biosystems, a Canada-based Bio-printing company, attempts to achieve improved accuracy in developing microfluidic platforms equipped with an on-printhead crosslinking system that can print bioinks with a coaxial shell.
  • In 2018, Prellis Biologics, in collaboration with BIOC Group, a leading Bio-printing company, released one of the first systems using two-photons stereolithography to the market, named Holograph X, with a special solution to increase the 3D printing speed by using a parallel set of photons, i.e., a multiphoton technology, to simultaneously cure millions of points in the bioink and turn to achieve Bio-printing speeds of up to 250,000 voxels/second. Some advanced technologies include high resolution, high speed, high accuracy, and 4D bioprinters. Poietis and ROKIT Healthcare are now offering 4D Bio-printing systems. Poietis’s 4D bioprinter, NGB-R, is a laser-assisted Bio-printing system based on four single-cell resolution technologies: computer-assisted design, automated, robotic Bioprinting, in-line monitoring, and tissue formation modeling. It enables true versatility of Bio-printing (from cell to spheroids) and offers the possibility of large biomaterials and hydrogels.


Market Segmentation by Components

  • 3d Bioprinters
  • Bio-Inks

Market Segmentation by Application

  • Research
  • Clinical

Market Segmentation by Material

  • Living Cells
  • Hydrogels
  • Extracellular Matrices
  • Others


A. The global Bioprinting market is moderately dynamic, with a few key international players and a large pool of start-up vendors that have emerged in recent years offering a comprehensive range of bioprinters.
B. Bioprinting vendors are facing huge competition from many established vendors and emerging companies to become highly competitive.
C. Furthermore, the market is experiencing an increase in the product launches from various vendors coupled with R&D activities, thus enabling vendors to expand their presence, enhance market growth, and sustain their market position in the global market.
D. Increasing funding and investments by public and private entities, including large companies and governments, are expected to enable emerging international companies and start-ups to develop bioprinters with applications in wide therapeutic areas. Many start-ups are coming up with 3D reconstruction software to be used by researchers for Bio-printing and thus are contributing to the growth of the Bio-printing market. The vendors are still facing regulatory approvals and ethical issues restricting them from growing in the market. Vendor's activities in the Bio-printing market include:
  • Expansion activities are helping the vendors strengthen the global distribution networks and thus allowing the players to explore untapped opportunities.
  • Large-scale investments and funding in the Bio-printing market through varied conglomerates and investments firms
  • Forging partnerships and collaborations with well-established manufacturers cementing the footprints of the players
  • Active Mergers and acquisitions play a crucial role in the smooth functioning of the growth cycle.
  • A diverse range of bioprinters and bio-inks are being offered.
  • The market is witnessing a surge in technological advancements in the field of Bio-printing, and several new product launches can be witnessed.
  • Several vendors are now focusing on developing low-cost, high-resolution, speed, and accuracy bioprinters. BIOC, Advanced Solutions, and ROKIT Healthcare are one of the top companies focused on offering cost-effective 3D bioprinters.
  • Several new start-up companies are entering the market with the increased funding being received by the government and private entities.
  • The market is witnessing a large number of pure players for bioprinters.
E. Vendors are engaged in developing all sorts of tissues ranging from the 3D bio-printed human testicle cells produced at the University of British Columbia to the bio-printed liver tissues of T&R Biofab. The 3D bioprinting market will have a more significant impact on patient treatment through engineered organ replacements. The notable growth of 3D printing has simplified pharmaceutical applications, enabling the development of customized drug delivery systems and drug screening for individual patients, escalating from conventional approaches that primarily rely on transgenic animal experiments and mass production.

Key Vendors

  • Organovo Holdings
  • BICO
  • Advanced Solutions (ASI)

Other Prominent Vendors

  • Aspect Biosystems
  • Brinter
  • Cellbricks
  • CollPlant
  • Cyfuse Biomedical
  • 3D Bio-printing Solutions
  • 3D Systems
  • 3DBio Therapeutics
  • Desktop Metal
  • Foldink
  • Formlabs
  • FELIXprinters
  • Fluicell
  • GeSiM
  • Hangzhou Jienuofei Biotechnology
  • Inventia Life Science
  • LIfe SI
  • Medprin
  • Next Big Innovation Labs
  • Ourobionics
  • Poietis
  • Precise Bio
  • Prellis Biologics
  • ROKIT Healthcare
  • Stratasys
  • TissueLabs


The Research Organizations & Academic Institutes segment has the highest revenue of $276.14 million in 2021 and thus holds the highest market share. North America dominates with an increasing number of research organizations and academic institutes that research Bioprinting and the adoption of bioprinting technologies and thus account for the highest market share. Several US-based research organizations and academic institutes have adopted advanced bioprinting technologies, driven by their increasing collaborations with the leading players to develop 3D functional tissue and organ models. With the growing focus on tissue engineering, and cell and gene therapy, regenerative medicine companies’ segment is expected to witness significant growth during the forecast period with the highest CAGR of 19.47%.

Market Segmentation by End-User

  • RO & AT
  • Biopharmaceutical Companies
  • RM Companies
  • Others


  • The growing rate of medical device manufacturers worldwide has fueled the demand for advanced technologies. Most leading medical device and pharmaceutical companies focus on improving their product portfolio worldwide. The demand in this market is expected to surge in response to the lack of organ donors in adequate numbers. With research and development investment and funding to research organizations and start-up companies is increasing significantly, the market will gain from increasing growth opportunities in the coming years.
  • In the past few years, Bio-printing technology has been increasingly preferred by surgeons and patients to precisely perform and plan reconstructive surgery. Therefore, critical developers of Bio-printing are now increasing their product portfolio with the launch of bioprinters and devices as part of their manufacturing strategy, which is expected to provide opportunities for market growth in the forecast period.
  • North America and Europe dominate the bio-printing market. Ongoing research on RM and advancements in tissue engineering are being aimed at regenerating damaged tissues and organs with the help of bioprinters. Increasing focus on regenerative and personalized medicine is driving the growth of the Bio-printing market in North America and Europe. Several vendors are coming up with more technological advancements in Bioprinting. The enhancement in printing resolution, speed, and cost reduction are the most common challenges that will continue to be faced in the upcoming years.

Market Segmentation by Geography

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • APAC
  • Japan
  • China
  • South Korea
  • India
  • Australia
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • South Africa


1. How big is the global 3D bioprinting market?
2. What is the growth rate of the bio-printing market?
3. What are the growth factors in the bio-printing market?
4. Who are the key players in the bio-printing market?
5. What are the latest trends in the bio-printing market?

Table of Contents

1 Research Methodology2 Research Objectives3 Research Process
4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.1.3 Market Estimation Caveats
4.2 Base Year
4.3 Scope of the Study
4.3.1 Market Segmentation by Component
4.3.2 Market Segmentation by Application
4.3.3 Market Segmentation by Material
4.3.4 Market Segmentation by End-user
4.3.5 Market Segmentation by Geography
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 Market at a Glance
7 Introduction
7.1 Overview
8 Premium Insights
8.1 Market Overview
9 Market Opportunities & Trends
9.1 Emergence of 4D Bioprinting
9.2 Rise in Focus on 3D Organ Bioprinting
9.3 High Focus on Personalized Medicine
10 Market Growth Enablers
10.1 Surge in Focus on Regenerative Medicine
10.2 Advances in Bioprinting Technologies
10.3 Rise in Funding for R&D Initiatives
11 Market Restraints
11.1 High Cost of Bioprinting Technologies
11.2 Bioethical and Legal Issues
11.3 Regulatory Barriers for Bioprinting Market
12 Market Landscape
12.1 Market Overview
12.2 Market Size & Forecast
12.2.1 Insights by Components
12.2.2 Insights by Application
12.2.3 Insights by Material
12.2.4 Insights by End-user
12.2.5 Insights by Geography
12.3 Five Forces Analysis
12.3.1 Threat of New Entrants
12.3.2 Bargaining Power of Suppliers
12.3.3 Bargaining Power of Buyers
12.3.4 Threat of Substitutes
12.3.5 Competitive Rivalry
13 Component
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 3D Bioprinters
13.3.1 Market Overview
13.3.2 Market Size & Forecast
13.3.3 Market by Geography
13.4 Bioinks
13.4.1 Market Overview
13.4.2 Market Size & Forecast
13.4.3 Market by Geography
14 Application
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 Research
14.3.1 Market Overview
14.3.2 Market Size & Forecast
14.3.3 Market by Geography
14.4 Clinical
14.4.1 Market Overview
14.4.2 Market Size & Forecast
14.4.3 Market by Geography
15 Material
15.1 Market Snapshot & Growth Engine
15.2 Market Overview
15.3 Living Cells
15.3.1 Market Overview
15.3.2 Market Size & Forecast
15.3.3 Market by Geography
15.4 Hydrogels
15.4.1 Market Overview
15.4.2 Market Size & Forecast
15.4.3 Market by Geography
15.5 Extracellular Matrices
15.5.1 Market Overview
15.5.2 Market Size & Forecast
15.5.3 Market by Geography
15.6 Others
15.6.1 Market Overview
15.6.2 Market Size & Forecast
15.6.3 Market by Geography
16 End-user
16.1 Market Snapshot & Growth Engine
16.2 Market Overview
16.3 Research Organization & Academic Institutes
16.3.1 Market Overview
16.3.2 Market Size & Forecast
16.3.3 Market by Geography
16.4 Biopharmaceutical Companies
16.4.1 Market Overview
16.4.2 Market Size & Forecast
16.4.3 Market by Geography
16.5 Rm Companies
16.5.1 Market Overview
16.5.2 Market Size & Forecast
16.5.3 Market by Geography
16.6 Others
16.6.1 Market Overview
16.6.2 Market Size & Forecast
16.6.3 Market by Geography
17 Geography
17.1 Market Snapshot & Growth Engine
17.2 Geographic Overview
18 North America
18.1 Market Overview
18.2 Market Size & Forecast
18.3 North America: Component
18.4 North America: Application
18.5 North America: Material
18.6 North America: End-user
18.7 Key Countries
18.7.1 Us: Market Size & Forecast
18.7.2 Canada: Market Size & Forecast
19 Europe
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Europe: Component
19.4 Europe: Application
19.5 Europe: Material
19.6 Europe: End-user
19.7 Key Countries
19.7.1 Germany: Market Size & Forecast
19.7.2 France: Market Size & Forecast
19.7.3 Uk: Market Size & Forecast
19.7.4 Spain: Market Size & Forecast
19.7.5 Italy: Market Size & Forecast
20 Apac
20.1 Market Overview
20.2 Market Size & Forecast
20.3 Apac: Component
20.4 Apac: Application
20.5 Apac: Material
20.6 Apac: End-user
20.7 Key Countries
20.7.1 Japan: Market Size & Forecast
20.7.2 China: Market Size & Forecast
20.7.3 South Korea: Market Size & Forecast
20.7.4 India: Market Size & Forecast
20.7.5 Australia: Market Size & Forecast
21 Latin America
21.1 Market Overview
21.2 Market Size & Forecast
21.3 Latin America: Component
21.4 Latin America: Application
21.5 Latin America: Material
21.6 Latin America: End-user
21.7 Key Countries
21.7.1 Brazil: Market Size & Forecast
21.7.2 Mexico: Market Size & Forecast
21.7.3 Argentina: Market Size & Forecast
22 Middle East & Africa
22.1 Market Overview
22.2 Market Size & Forecast
22.3 Middle East & Africa: Component
22.4 Middle East & Africa: Application
22.5 Middle East & Africa: Material
22.6 Middle East & Africa: End-user
22.7 Key Countries
22.7.1 Turkey: Market Size & Forecast
22.7.2 Saudi Arabia: Market Size & Forecast
22.7.3 Uae: Market Size & Forecast
22.7.4 South Africa: Market Size & Forecast
23 Competitive Landscape
23.1 Competition Overview
23.2 Market Share Analysis
23.2.1 Organovo Holdings
23.2.2 Bico
23.2.3 Advanced Solutions Life Sciences (Asls)
24 Key Company Profiles
24.1 Organovo Holdings
24.1.1 Business Overview
24.1.2 Product Offerings
24.1.3 Key Strategies
24.1.4 Key Strengths
24.1.5 Key Opportunities
24.2 Bico
24.2.1 Business Overview
24.2.2 Product Offerings
24.2.3 Key Strategies
24.2.4 Key Strengths
24.2.5 Key Opportunities
24.3 Advanced Solutions
24.3.1 Business Overview
24.3.2 Product Offerings
24.3.3 Key Strategies
24.3.4 Key Strengths
24.3.5 Key Opportunities
25 Other Prominent Vendors
25.1 Aspect Biosystems
25.1.1 Business Overview
25.1.2 Product Offerings
25.2 Biolife4D
25.2.1 Business Overview
25.2.2 Product Offerings
25.3 Brinter
25.3.1 Business Overview
25.3.2 Product Offerings
25.4 Cellbricks
25.4.1 Business Overview
25.4.2 Product Offerings
25.5 Collplant
25.5.1 Business Overview
25.5.2 Product Offerings
25.6 Cyfuse Biomedical
25.6.1 Business Overview
25.6.2 Product Offerings
25.7 3D Bioprinting Solutions
25.7.1 Business Overview
25.7.2 Product Offerings
25.8 3D Systems
25.8.1 Business Overview
25.8.2 Product Offerings
25.9 3Dbio Therapeutics
25.9.1 Business Overview
25.9.2 Product Offerings
25.10 Desktop Metal
25.10.1 Business Overview
25.10.2 Product Offerings
25.11 Foldink
25.11.1 Business Overview
25.11.2 Product Offerings
25.12 Formlabs
25.12.1 Business Overview
25.12.2 Product Offerings
25.13 Felixprinters
25.13.1 Business Overview
25.13.2 Product Offerings
25.14 Fluicell
25.14.1 Business Overview
25.14.2 Product Offerings
25.15 Gesim
25.15.1 Business Overview
25.15.2 Product Offerings
25.16 Hangzhou Jienuofei Biotechnology
25.16.1 Business Overview
25.16.2 Product Offerings
25.17 Inventia Life Science
25.17.1 Business Overview
25.17.2 Product Offerings
25.18 Life Si
25.18.1 Business Overview
25.18.2 Product Offerings
25.19 Medprin
25.19.1 Business Overview
25.19.2 Product Offerings
25.20 Next Big Innovation Labs
25.20.1 Business Overview
25.20.2 Product Offerings
25.21 Nscrypt
25.21.1 Business Overview
25.21.2 Product Offerings
25.22 Ourobionics
25.22.1 Business Overview
25.22.2 Product Offerings
25.23 Poietis
25.23.1 Business Overview
25.23.2 Product Offerings
25.24 Precise Bio
25.24.1 Business Overview
25.24.2 Product Offerings
25.25 Prellis Biologics
25.25.1 Business Overview
25.25.2 Product Offerings
25.26 Rokit Healthcare
25.26.1 Business Overview
25.26.2 Product Offerings
25.27 Regenhu
25.27.1 Business Overview
25.27.2 Product Offerings
25.28 Stratasys
25.28.1 Business Overview
25.28.2 Product Offerings
25.29 Tissuelabs
25.29.1 Business Overview
25.29.2 Product Offerings
26 Report Summary
26.1 Key Takeaways
26.2 Strategic Recommendations
27 Quantitative Summary
27.1 Market by Geography
27.2 Market by Component
27.3 Market by Application
27.4 Market by Material
27.5 Market by End-user
27.6 North America by Component
27.7 North America by Application
27.8 North America by Material
27.9 North America by End-user
27.10 Europe by Component
27.11 Europe by Application
27.12 Europe by Material
27.13 Europe by End-user
27.14 APAC by Component
27.15 APAC by Application
27.16 APAC by Material
27.17 APAC by End-user
27.18 Latin America by Component
27.19 Latin America by Application
27.20 Latin America by Material
27.21 Latin America by End-user
27.22 Middle East & Africa by Component
27.23 Middle East & Africa by Application
27.24 Middle East & Africa by Material
27.25 Middle East & Africa by End-user
28 Appendix
28.1 Abbreviations

Companies Mentioned

  • Organovo Holdings
  • BICO
  • Advanced Solutions (ASI)
  • Aspect Biosystems
  • Brinter
  • Cellbricks
  • CollPlant
  • Cyfuse Biomedical
  • 3D Bio-printing Solutions
  • 3D Systems
  • 3DBio Therapeutics
  • Desktop Metal
  • Foldink
  • Formlabs
  • FELIXprinters
  • Fluicell
  • GeSiM
  • Hangzhou Jienuofei Biotechnology
  • Inventia Life Science
  • LIfe SI
  • Medprin
  • Next Big Innovation Labs
  • Ourobionics
  • Poietis
  • Precise Bio
  • Prellis Biologics
  • ROKIT Healthcare
  • Stratasys
  • TissueLabs


Our research comprises a mix of primary and secondary research. The secondary research sources that are typically referred to include, but are not limited to, company websites, annual reports, financial reports, company pipeline charts, broker reports, investor presentations and SEC filings, journals and conferences, internal proprietary databases, news articles, press releases, and webcasts specific to the companies operating in any given market.

Primary research involves email interactions with the industry participants across major geographies. The participants who typically take part in such a process include, but are not limited to, CEOs, VPs, business development managers, market intelligence managers, and national sales managers. We primarily rely on internal research work and internal databases that we have populated over the years. We cross-verify our secondary research findings with the primary respondents participating in the study.